Compare · NBTX vs NVO
NBTX vs NVO
Side-by-side comparison of Nanobiotix S.A. (NBTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 105.4x NBTX ($1.74B).
- Over the past year, NBTX is up 633.5% and NVO is down 45.2% - NBTX leads by 678.7 points.
- NBTX has been more active in the news (24 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for NBTX).
- Company
- Nanobiotix S.A.
- Novo Nordisk A/S
- Price
- $33.38-5.28%
- $41.38+0.90%
- Market cap
- $1.74B
- $183.15B
- 1M return
- -24.86%
- -10.23%
- 1Y return
- +633.52%
- -45.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 24
- 8
- Recent ratings
- 3
- 25
Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NBTX
- SEC Form S-8 filed by Nanobiotix S.A.
- SEC Form 6-K filed by Nanobiotix S.A.
- SEC Form 6-K filed by Nanobiotix S.A.
- Nanobiotix Provides First Quarter 2026 Operational and Financial Update
- SEC Form 6-K filed by Nanobiotix S.A.
- Nanobiotix Joins the Euronext Tech Leaders Index
- SEC Form 6-K filed by Nanobiotix S.A.
- SEC Form 6-K filed by Nanobiotix S.A.
- NANOBIOTIX Announces Closing of Global Offering
- SEC Form 6-K filed by Nanobiotix S.A.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care